



# Bangladesh: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

Project Name	Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
Project Number	55077-001	
Country	Bangladesh	
Project Status	Active	
Project Type / Modality of Assistance	Loan	
Source of Funding / Amount	Loan 4078-BAN: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
	Concessional ordinary capital resources lending	US\$ 470.00 million
	Loan 4079-BAN: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility	
	Ordinary capital resources	US\$ 470.00 million
Strategic Agendas	Inclusive economic growth Regional integration	
Drivers of Change	Knowledge solutions Partnerships	
Sector / Subsector	Health - Disease control of communicable disease	
Gender Equity and Mainstreaming	Effective gender mainstreaming	
Description	The project will provide the Government of Bangladesh with timely financing for procuring safe and effective vaccines against the coronavirus disease (COVID-19) based on an agreed list of eligible expenditures. It will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX). Ongoing technical assistance (TA) will help strengthen the vaccine delivery system. The project is aligned with three operational priorities of the Asian Development Bank (ADB) Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. It is also aligned with ADB's country partnership strategy for Bangladesh, 2016-2020 in the priority areas of improving human capital and health care, and promoting gender equality	
Project Rationale and Linkage to Country/Regional Strategy	Since the first case of COVID-19 was confirmed in Bangladesh in March 2020, 776,257 cases have been confirmed and 12,005 people have died from the virus as of 11 May 2021. The pandemic has resulted in high costs to the country's overall health, well-being, and the economy. Bangladesh is currently experiencing a second wave, which has led to a rapid spike in new cases, with the highest number of deaths (112) in a single day on 19 April 2021. The resurgence in infections threatens to incur prolonged health and economic costs. Recognizing the need for vaccinations, the government acted swiftly to roll out vaccinations starting 7 February 2021. The government has secured a pipeline of 33.2 million doses and more than 9.3 million people have been vaccinated as of 9 May 2021. The government aims to inoculate 80% of its population. However, Bangladesh's vaccine needs have not been fully met and a significant share of the targeted population is yet to be vaccinated. It requires timely financing support to procure safe and effective vaccines, and avert prolonged risks from the pandemic.	
Impact	Accelerated health, social, and economic recovery of the COVID-19 affected population in Bangladesh	
<b>Project Outcome</b>		
Description of Outcome	Target populations vaccinated against COVID-19	
<b>Progress Toward Outcome</b>		
<b>Implementation Progress</b>		
Description of Project Outputs	Safe and effective COVID-19 vaccines delivered	
Status of Implementation Progress (Outputs, Activities, and Issues)		
Geographical Location	Nation-wide	
<b>Safeguard Categories</b>		
Environment	C	
Involuntary Resettlement	C	
Indigenous Peoples	C	
<b>Summary of Environmental and Social Aspects</b>		
Environmental Aspects	The project will support the procurement of vaccines and will not entail civil works or other activities with potential for significant adverse impacts on the environment.	
Involuntary Resettlement	The project will not require any land acquisition or lead to any involuntary resettlement impacts or involuntary land use restriction.	

Indigenous Peoples The tribes, minor races, ethnic sects, and ethnic communities will not be targeted as a distinct and vulnerable IP group but may benefit as individual IPs.

#### Stakeholder Communication, Participation, and Consultation

##### During Project Design

During Project Implementation The participation plan will not be prepared because while the participation of CSOs has been envisaged, CSOs are not the major interest holder in this program.

#### Business Opportunities

**Procurement** Procurement will be undertaken in a manner consistent with simplified and expedient procedures permitted under the ADB Procurement Policy (2017, as amended from time to time) and Procurement Regulations for ADB Borrowers (2017, as amended from time to time). Since the project will be financed under APVAX, ADB member country eligibility restrictions will be waived and universal procurement will apply. The procurement of a proportion of the vaccines may be done through COVAX. In addition, given the severely constrained vaccine market, the MOHFW may negotiate directly with vaccine manufacturers to agree on bilateral contracts, and direct contracting with UNICEF. Before being confirmed as an eligible expenditure under the loan, ADB will review all bilateral vaccine agreements. Value for money in procurement will be achieved by (i) selecting vaccines that are best suited to the domestic supply chain; (ii) identifying vaccines that will efficiently meet the project disbursement conditions; (iii) engaging with manufacturers that have advantageous vaccine delivery timelines; and (iv) entering into agreements on terms and conditions that are reasonable, noting the currently constrained market for vaccines globally. ADB's Anticorruption Policy (1998, as amended to date) will apply to all contracts to be financed under the loan.

Responsible ADB Officer	Hoque, Uzma S.
Responsible ADB Department	South Asia Department
Responsible ADB Division	Human and Social Development Division, SARD
Executing Agencies	Finance Division, MOF (EA) Mr. Molla Mansur Ahmed MONWARA@ERD.GOV.BD Bangladesh Secretariat, Dhaka-1000 Bangladesh

#### Timetable

Concept Clearance	30 Dec 2022
Fact Finding	29 Mar 2021 to 05 Apr 2021
MRM	10 May 2021
Approval	22 Jun 2021
Last Review Mission	-
Last PDS Update	22 Jun 2021

## Loan 4078-BAN

Milestones					
Approval	Signing Date	Effectivity Date	Closing		
			Original	Revised	Actual
22 Jun 2021	24 Jun 2021	05 Jul 2021	30 Nov 2024	-	-

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	470.00	Cumulative Contract Awards			
ADB	470.00	18 Oct 2021	447.27	0.00	95%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	0.00	18 Oct 2021	441.30	0.00	94%

## Loan 4079-BAN

Milestones					
Approval	Signing Date	Effectivity Date	Closing		
			Original	Revised	Actual
22 Jun 2021	24 Jun 2021	05 Jul 2021	30 Nov 2024	-	-

Financing Plan		Loan Utilization			
	Total (Amount in US\$ million)	Date	ADB	Others	Net Percentage
Project Cost	470.00	Cumulative Contract Awards			
ADB	470.00	18 Oct 2021	300.00	0.00	64%
Counterpart	0.00	Cumulative Disbursements			
Cofinancing	0.00	18 Oct 2021	450.00	0.00	96%

---

Project Page	<a href="https://www.adb.org/projects/55077-001/main">https://www.adb.org/projects/55077-001/main</a>
Request for Information	<a href="http://www.adb.org/forms/request-information-form?subject=55077-001">http://www.adb.org/forms/request-information-form?subject=55077-001</a>
Date Generated	03 November 2021

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.